Brolucizumab for CNV Associated With Pathologic Myopia

Inclusion Criteria: * Able to read (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent form or a family member) and understand the informed consent form and willing to sign the informed consent form. * Signed informed consent form. * Men and women ≥ 18 years of age. * Willing, committed, and able to return for all clinic visits and complete all study-related procedures. * Myopia of greater than or equal to -6 D OR axial length of greater than (if the spherical myopic equivalent is \<6.0 diopters, then the patient should have myopic changes in the macula: lacquer cracks, focal chorioretinal atrophy, posterior staphyloma) or equal to 26.5 mm. * Active subfoveal or juxtafoveal (within 1 to 199 μm of the center of the fovea) CNV secondary to pathologic myopia as defined by leakage on FA. * Transparent optical media and possibility to mydriasis. * Best corrected visual acuity at least 20/200 Equivalent of Snellen (ETDRS). Exclusion Criteria: * Ocular media of insufficient quality to obtain fundus and OCT images in the study eye * Recurrent mCNV in the study eye * History or presence of CNV with an origin other than pathologic myopia in the study eye * Ocular inflammation or external ocular inflammation in the study eye * Concurrent disease in the study eye that would compromise BCVA or require medical or surgical intervention during the study period * Any ocular disorder in the study eye that, in the opinion of t…